PYX-201, EDB+FN is an attractive target in oncology: Insights from protein expression analysis of solid tumors – Abstract Number: 2908 By lsc-webmaster PYX-201, EDB+FN is an attractive target in oncology: Insights from protein expression analysis of solid tumors – Abstract Number: 2908 Read More »
PYX-201, a stroma-targeting ADC composed of an anti-EDB+FN antibody conjugated to Auristatin0101, demonstrates strong anti-tumor efficacy across multiple human cancer indications in pre-clinical PDX tumor models – Abstract Number: 742 By Dan PYX-201, a stroma-targeting ADC composed of an anti-EDB+FN antibody conjugated to Auristatin0101, demonstrates strong anti-tumor efficacy across multiple human cancer indications in pre-clinical PDX tumor models – Abstract Number: 742 Read More »
Extracellular proteolytic cleavage of peptide-linked antibody-drug conjugates promotes bystander killing of cancer cells – Abstract Number: 4837 By Dan Extracellular proteolytic cleavage of peptide-linked antibody-drug conjugates promotes bystander killing of cancer cells – Abstract Number: 4837 Read More »
PYX-106, Gene expression correlation of immune checkpoint molecules Siglec-15 and PD-L1 varies widely by cancer indication – Abstract Number: 1373 By walid PYX-106, Gene expression correlation of immune checkpoint molecules Siglec-15 and PD-L1 varies widely by cancer indication – Abstract Number: 1373 Read More »
CD40 Agonism Remodels the Tumor Immune Microenvironment in Locally Advanced Esophageal/Gastroesophageal Junction Cancer – Poster Number: 1361 By Jonathan CD40 Agonism Remodels the Tumor Immune Microenvironment in Locally Advanced Esophageal/Gastroesophageal Junction Cancer – Poster Number: 1361 Read More »
PYX-102, an Anti-KLRG1 Antibody, Enhances Cytotoxic Activity of CD8 T cells from PBMC and Human Tumor Samples by Blocking the Interaction Between KLRG1 and Cadherins Poster Number: 572 By Jonathan PYX-102, an Anti-KLRG1 Antibody, Enhances Cytotoxic Activity of CD8 T cells from PBMC and Human Tumor Samples by Blocking the Interaction Between KLRG1 and Cadherins Poster Number: 572 Read More »
First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of anti Siglec-15 PYX-106 in Subjects with Advanced Solid Tumors Poster Number: 756 By Jonathan First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of anti Siglec-15 PYX-106 in Subjects with Advanced Solid Tumors Poster Number: 756 Read More »
A First-in-Human Phase 1 Clinical Study Evaluating Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of the EDB+FN targeting ADC PYX-201 in Participants with Advanced Solid Tumors Poster Number: 762 By Jonathan A First-in-Human Phase 1 Clinical Study Evaluating Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of the EDB+FN targeting ADC PYX-201 in Participants with Advanced Solid Tumors Poster Number: 762 Read More »
A Phase 2 Trial with a Safety Lead-in to Evaluate the Addition of Sotigalimab, a CD40 Agonistic Monoclonal Antibody, to Standard-of-Care Doxorubicin for the Treatment of Advanced Sarcoma By lsc-webmaster A Phase 2 Trial with a Safety Lead-in to Evaluate the Addition of Sotigalimab, a CD40 Agonistic Monoclonal Antibody, to Standard-of-Care Doxorubicin for the Treatment of Advanced Sarcoma Read More »
Tissue Assessment of Therapeutic Responses to Neoadjuvant SCRT with and without Anit-CD40 Immunotherapy Sotigalimab (Sotiga) in Rectal Cancer By lsc-webmaster Tissue Assessment of Therapeutic Responses to Neoadjuvant SCRT with and without Anit-CD40 Immunotherapy Sotigalimab (Sotiga) in Rectal Cancer Read More »
